- Home
- PD vs JANX Comparison
PD vs JANX Comparison
Compare PD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- JANX
- Stock Information
- Founded
- PD 2009
- JANX 2017
- Country
- PD United States
- JANX United States
- Employees
- PD N/A
- JANX N/A
- Industry
- PD Computer Software: Prepackaged Software
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- PD Technology
- JANX Health Care
- Exchange
- PD Nasdaq
- JANX Nasdaq
- Market Cap
- PD 1.5B
- JANX 1.4B
- IPO Year
- PD 2019
- JANX 2021
- Fundamental
- Price
- PD $16.41
- JANX $24.38
- Analyst Decision
- PD Hold
- JANX Strong Buy
- Analyst Count
- PD 9
- JANX 10
- Target Price
- PD $18.33
- JANX $79.50
- AVG Volume (30 Days)
- PD 2.8M
- JANX 645.3K
- Earning Date
- PD 09-03-2025
- JANX 11-05-2025
- Dividend Yield
- PD N/A
- JANX N/A
- EPS Growth
- PD N/A
- JANX N/A
- EPS
- PD N/A
- JANX N/A
- Revenue
- PD $483,608,000.00
- JANX $439,000.00
- Revenue This Year
- PD $9.50
- JANX N/A
- Revenue Next Year
- PD $7.41
- JANX $591.60
- P/E Ratio
- PD N/A
- JANX N/A
- Revenue Growth
- PD 8.20
- JANX N/A
- 52 Week Low
- PD $13.70
- JANX $21.97
- 52 Week High
- PD $21.98
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- PD 51.81
- JANX 51.47
- Support Level
- PD $15.91
- JANX $23.62
- Resistance Level
- PD $17.29
- JANX $25.35
- Average True Range (ATR)
- PD 0.80
- JANX 1.15
- MACD
- PD -0.03
- JANX 0.17
- Stochastic Oscillator
- PD 69.55
- JANX 61.64
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.